New Alzheimer's drug tested for safety in Early-Stage patients
NCT ID NCT04602624
Summary
This study tested the safety and side effects of an investigational drug called SAGE-718 in people with early Alzheimer's disease or mild cognitive impairment. It involved 26 participants and aimed to see if the drug was well-tolerated while also checking for any effects on memory, thinking, and mood. The main goal was to gather safety information to guide future research, not to prove the drug cures the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sage Investigational Site
Phoenix, Arizona, 85044, United States
-
Sage Investigational Site
Redlands, California, 92374, United States
-
Sage Investigational Site
Miami, Florida, 33137, United States
-
Sage Investigational Site
St. Petersburg, Florida, 33713, United States
-
Sage Investigational Site
Decatur, Georgia, 30030, United States
-
Sage Investigational Site
Decatur, Georgia, 30033, United States
-
Sage Investigational Site
Gaithersburg, Maryland, 20877, United States
-
Sage Investigational Site
Farmington Hills, Michigan, 48334, United States
-
Sage Investigational Site
Omaha, Nebraska, 68130, United States
-
Sage Investigational Site
North Canton, Ohio, 44720, United States
Conditions
Explore the condition pages connected to this study.